// App-Quantinova.ai

PD4-03 : OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Researchers

Presenter

  • Mark Robson

Principal Investigators

  • Seock-Ah Im

  • Elzbieta Senkus

  • Binghe Xu

  • Susan Domchek

  • Norikazu Masuda

  • Suzette Delaloge

  • Wei Li

  • Nadine Tung

  • Anne Armstrong

  • Wendy Bannister

  • Carsten Goessl

  • Allison Allen

  • Pierfranco Conte

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Medical University of Gdansk, Gdansk, Poland

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

  • Basser Center, University of Pennsylvania, Philadelphia, PA

  • National Hospital Organization Toneyama National Hospital, Toyonaka, Japan

  • Institut Gustave-Roussy, Villejuif, France

  • The First Hospital of Jilin University, Changchun, China

  • Beth Israel Deaconess Medical Center/ Dana-Farber Cancer Institute, Boston, MA

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • AstraZeneca, Gaithersburg, MD

  • University of Padova and Istituto Oncologico Veneto IOV IRCCS, Padova, Italy

Locations

  • United States

  • Republic of South Korea

  • Poland

  • China

  • Japan

  • France

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

  • BRCA mutation

Drug/Treatment

  • Capecitabine

  • Vinorelbine

  • Eribulin

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02000622

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved